| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criterion 7. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | ethosuximide (Epesri®) |
| Formulation | 250 mg capsule |
| Reference number | 4984 |
| Indication | Selective control of absence seizures (petit mal) even when complicated by grand mal. It is also indicated for myoclonic seizures |
| Company | Strides Pharma UK Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 28/10/2021 |